CAJ | 학술논문

建立了LC-MS/MS法测定人血浆中的文拉法辛,研究了24例男性健康受试者双周期、交叉、随机、单剂量口服盐酸文拉法辛胶囊50 mg后的药动学和相对生物利用度.受试与参比制剂的主要药动学参数分别为:c_(max)(71.1±29.9)和(71.2±26.6)ng/m1.t_(max)(2.31±0.67)和(2.31±0.75)h:t_(1/2)(4.68±1.30)和(4.83±1.39)h;AUC_(0→24)(534.7±334.6)和(543.9±370.3)h·ng·ml~(-1),相对生物利用度为(101.8±18.3)%,两种制剂具有生物等效性.
건립료LC-MS/MS법측정인혈장중적문랍법신,연구료24례남성건강수시자쌍주기、교차、수궤、단제량구복염산문랍법신효낭50 mg후적약동학화상대생물이용도.수시여삼비제제적주요약동학삼수분별위:c_(max)(71.1±29.9)화(71.2±26.6)ng/m1.t_(max)(2.31±0.67)화(2.31±0.75)h:t_(1/2)(4.68±1.30)화(4.83±1.39)h;AUC_(0→24)(534.7±334.6)화(543.9±370.3)h·ng·ml~(-1),상대생물이용도위(101.8±18.3)%,량충제제구유생물등효성.
A LC-MS/MS method was established for the determination of venlafaxine in human plasma. According to a randomized two-period crossover design, the pharmacokinetics and bioequivalence after single dose oral administration of test and reference capsules in 24 healthy volunteers were investigated. The pharmacokinetic parameters of test and reference capsules were as follows: c_(max) (71.1±29.9) and (71.2±26.6) ng/ml, t_(max) (2.31±0.67) and (2.31± relative bioavailability of the preparation was (101.8±18.3) %. The two formulations are bioequivalent.